“Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s150. doi:10.25251/skin.7.supp.150.